scholarly journals OP35.02: Prenatal detection of congenital heart defects is hampered by overweight and obesity: review on 19,687 pregnant women

2011 ◽  
Vol 38 (S1) ◽  
pp. 155-155
Author(s):  
A. Schroer ◽  
J. Weichert ◽  
K. Kelling ◽  
A. Stepien
Keyword(s):  
Pregnant Women ◽  
Congenital Heart Defects ◽  
Congenital Heart ◽  
Heart Defects ◽  
Overweight And Obesity ◽  
Prenatal Detection

scholarly journals Proximity to risk-appropriate perinatal hospitals for pregnant women with congenital heart defects in New York state

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Lauren E. Schlichting ◽  
Tabassum Insaf ◽  
George Lui ◽  
Ali Zaidi ◽  
Alissa Van Zutphen
Keyword(s):  
New York ◽  
Pregnant Women ◽  
Congenital Heart Defects ◽  
Congenital Heart ◽  
Heart Defects ◽  
New York State ◽  
York State

scholarly journals Special statement: Proposed quality metrics to assess accuracy of prenatal detection of congenital heart defects

2020 ◽  
Vol 222 (6) ◽  
pp. B2-B9
Author(s):  
C. Andrew Combs ◽  
Afshan B. Hameed ◽  
Alexander M. Friedman ◽  
Iffath Abbasi Hoskins
Keyword(s):  
Congenital Heart Defects ◽  
Congenital Heart ◽  
Heart Defects ◽  
Quality Metrics ◽  
Prenatal Detection

Congenital heart defects and pregnancy: current view on the mechanisms of placental adaptation to circulatory hypoxia

2020 ◽  
Vol 19 (6) ◽  
pp. 70-82
Author(s):  
L.A. Rudyuk ◽  
◽  
O.S. Reshetnikova ◽  
Keyword(s):  
Pregnant Women ◽  
Congenital Heart Defects ◽  
Congenital Heart ◽  
Heart Defects ◽  
Preventive Therapy ◽  
Health Improvement ◽  
Current View ◽  
Compensatory Mechanisms ◽  
Circulatory Hypoxia ◽  
Fetoplacental Complex

In this review, we perform clinical and morphological analysis of the mechanisms underlying adaptation of the human placenta to hypoxia in the fetoplacental complex in pregnant women with congenital heart defects (CHDs). We assessed specific characteristics of macroscopic and microscopic structure of the placenta in women with this extragenital pathology. We descried morphological involutive dystrophic and compensatory mechanisms that develop in the placenta of women with impaired hemodynamics. We proposed molecular markers, whose investigation will clarify functional state of the placental barrier and ways of remodeling vascular-stromal components of the villous chorion. Potential risks associated with circulatory hypoxia in the mother-placenta-fetus system should be taken into account in the management of pregnant women with CHDs. Detection of placental maladaptation signs in mothers with CHDs will help to identify the risk group of newborns, organize preventive therapy, prophylaxis of diseases, health improvement, and treatment of newborns. Key words: compensatory and adaptive processes, hypoxia, immunohistochemistry, morphology, placenta

scholarly journals VP17.13: Timing of prenatal detection of isolated severe congenital heart defects

2020 ◽  
Vol 56 (S1) ◽  
pp. 127-127
Author(s):  
M.A. Lugthart ◽  
E. Verbaarschot ◽  
A. Nisselrooij ◽  
K. Kamp ◽  
E. Kleinrouweler ◽  
...  
Keyword(s):  
Congenital Heart Defects ◽  
Congenital Heart ◽  
Heart Defects ◽  
Prenatal Detection

OC190: Prenatal detection of congenital heart defects in a non-selected population of 30 139 fetuses

2004 ◽  
Vol 24 (3) ◽  
pp. 267-267
Author(s):  
E. Tegnander ◽  
W. Williams ◽  
O. J. Johansen ◽  
H. G. Blaas ◽  
S. H. Eik-Nes
Keyword(s):  
Congenital Heart Defects ◽  
Congenital Heart ◽  
Heart Defects ◽  
Prenatal Detection

scholarly journals Circulating LncRNAs as Novel, Non-Invasive Biomarkers for Prenatal Detection of Fetal Congenital Heart Defects

2016 ◽  
Vol 38 (4) ◽  
pp. 1459-1471 ◽  
Author(s):  
Meng Gu ◽  
Aibin Zheng ◽  
Wenjuan Tu ◽  
Jing Zhao ◽  
Lin Li ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Congenital Heart Defects ◽  
Congenital Heart ◽  
Heart Defects ◽  
Roc Curves ◽  
Differentially Expressed ◽  
Rt Pcr ◽  
Clinical Value ◽  
Roc Curve Analysis ◽  
Novel Biomarkers

Objectives: To explore the clinical value of circulating long non-coding RNAs (lncRNAs) as biomarkers to predict fetal congenital heart defects (CHD) in pregnant women. Methods: Differential expression of lncRNAs isolated from the plasma of pregnant women with typical fetal CHD or healthy controls was analyzed by microarray. Gene ontology (GO), pathway and network analysis were performed to study the function of the lncRNAs. Differentially expressed lncRNAs were validated in plasma samples from 62 pregnant women with typical CHD and 62 matched controls by RT-PCR. The sensitivity and specificity of each lncRNA in the diagnosis of fetal CHD was determined by ROC curve analysis. Results: Microarray analysis identified 3694 up-regulated and 3919 down-regulated (fold change ≥2.0) lncRNAs. The top ten significantly differentially expressed, CHD-associated lncRNAs were validated by RT-PCR. Five significantly up-regulated or down-regulated lncRNAs were identified: ENST00000436681, ENST00000422826, AA584040, AA709223 and BX478947 with the AUC of ROC curves calculated as 0.892, 0.817, 0.755, 0.882 and 0.886, respectively. Conclusions: Specific lncRNAs aberrantly expressed in the plasma of pregnant women with typical fetal CHD may play a key role in the development of CHD and may be used as novel biomarkers for prenatal diagnosis of fetal CHD.

scholarly journals Adverse Pregnancy Conditions Among Privately Insured Women With and Without Congenital Heart Defects

2020 ◽  
Vol 13 (6) ◽  
Author(s):  
Karrie F. Downing ◽  
Naomi K. Tepper ◽  
Regina M. Simeone ◽  
Elizabeth C. Ailes ◽  
Michelle Gurvitz ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Congenital Heart Defects ◽  
American Heart Association ◽  
Congenital Heart ◽  
American Heart ◽  
Heart Defects ◽  
Heart Association ◽  
Menstrual Period ◽  
Last Menstrual Period ◽  
Adverse Conditions

Background In women with congenital heart defects (CHD), changes in blood volume, heart rate, respiration, and edema during pregnancy may lead to increased risk of adverse outcomes and conditions. The American Heart Association recommends providers of pregnant women with CHD assess cardiac health and discuss risks and benefits of cardiac-related medications. We described receipt of American Heart Association–recommended cardiac evaluations, filled potentially teratogenic or fetotoxic (Food and Drug Administration pregnancy category D/X) cardiac-related prescriptions, and adverse conditions among pregnant women with CHD compared with those without CHD. Methods and Results Using 2007 to 2014 US healthcare claims data, we ascertained a retrospective cohort of women with and without CHD aged 15 to 44 years with private insurance covering prescriptions during pregnancy. CHD was defined as ≥1 inpatient code or ≥2 outpatient CHD diagnosis codes >30 days apart documented outside of pregnancy and categorized as severe or nonsevere. Log-linear regression, accounting for multiple pregnancies per woman, generated adjusted prevalence ratios (aPRs) for associations between the presence/severity of CHD and stillbirth, preterm birth, and adverse conditions from the last menstrual period to 90 days postpartum. We identified 2056 women with CHD (2334 pregnancies) and 1 374 982 women without (1 524 077 pregnancies). During the last menstrual period to 90 days postpartum, 56% of women with CHD had comprehensive echocardiograms and, during pregnancy, 4% filled potentially teratogenic or fetotoxic cardiac-related prescriptions. Women with CHD, compared with those without, experienced more adverse conditions overall (aPR, 1.9 [95% CI, 1.7–2.1]) and, specifically, obstetric (aPR, 1.3 [95% CI, 1.2–1.4]) and cardiac conditions (aPR, 10.2 [95% CI, 9.1–11.4]), stillbirth (aPR, 1.6 [95% CI, 1.1–2.4]), and preterm delivery (aPR, 1.6 [95% CI, 1.4–1.8]). More women with severe CHD, compared with nonsevere, experienced adverse conditions overall (aPR, 1.5 [95% CI, 1.2–1.9]). Conclusions Women with CHD have elevated prevalence of adverse cardiac and obstetric conditions during pregnancy; 4 in 100 used potentially teratogenic or fetotoxic medications, and only half received an American Heart Association–recommended comprehensive echocardiogram.

Sign in / Sign up

Export Citation Format

Share Document